Basel (CH), 16 May 2019 – Today, Lonza announced the launch of Capsugel® Zephyr™, its new dry-powder inhalation (DPI) capsule portfolio, the most complete portfolio of DPI capsules to meet the growing need for customized solutions for optimal pulmonary drug delivery.
Respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are on the rise globally and are among the most life-threatening. Lonza’s Capsule Delivery Solutions team developed Capsugel® Zephyr™ capsules as a portfolio of high-quality, highly customizable DPI capsules of different polymers and compositions, and product customization services to help address the specific needs of inhalation drug products manufacturers.
“Capsule-based DPI technology is quickly becoming the preferred DPI drug delivery platform for pulmonary delivery. It provides drug stability advantages, encourages patient compliance and is cost-effective to manufacture with various dose carrying capacity. With over 20 years of experience in manufacturing DPI- capsules, Lonza offers a uniquely customized portfolio of polymers to meet the growing need of inhalation DPI products for pulmonary drug delivery,” stated Stef Vanquickenborne, VP R&D, Lonza Pharma & Biotech.
The Capsugel® Zephyr™ capsule portfolio responds to the marketplace needs for comprehensive inhalation solutions that ensure end product efficacy with consistent and optimal release performance regardless of formulation characteristics or DPI device principles. With over three billion DPI capsule units delivered worldwide, Lonza offers a full-service inhalation drug-delivery approach based on proven particle engineering platforms, specialized encapsulation technologies as well as customized capsules for use with a large range of DPI devices. The portfolio is further supported by a global integrated supply chain, quality and regulatory support and Lonza’s advanced manufacturing network for associated services.
“With the launch of the Capsugel® Zephyr™ capsule portfolio, Lonza will offer full end-to-end solutions for capsule-based DPI products. Our specialized capsule technology provides our customers with the right solution to deliver optimal product performance for the pulmonary route; a testament to how patient-centricity and customer focus are at the heart of Lonza’s healthcare continuum,” remarked Fabio Invernizzi, VP Global Sales, Capsule Delivery Solutions, Lonza Pharma & Biotech.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Details
Investor Relations Officer
Lonza Group Ltd
Tel +41 61 316 8540
Dr. Sanna Fowler
Head of Public Relations
Lonza Pharma & Biotech
Tel +41 61 316 8929
Head of Global Marketing
Capsule Delivery Solutions
Tel +32 3 890 05 11
Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.